Skip to main content

Advertisement

SpringerLink
Log in

The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors

  • Original Paper
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

The aim of the study was to evaluate the effect of the agent SU-11248 (sunitinib malate) in the course from non-castration to castration LNCaP xenograft prostate tumors.

Methods

BALB/c nude mice were injected with human androgen-dependent prostate cancer cell line (LNCaP) and divided into two groups: castration and non-castration. Then the LNCaP-bearing mice were treated with sunitinib (40 mg/kg daily, 0.2 ml p.o. for 3 weeks). Both groups were paired with control groups in which the mice were given water by gavaging daily. The kidneys, livers, hearts, lungs, spleens, stomachs, intestines, skins, and other parts of all the mice were observed carefully during the study.

Results

At the end of the 3-week dosing schedule, the tumors of the sunitinib-treated mice grew significantly slower than those of control group. Adverse reactions were not significantly found in the mice. We examined the impact of sunitinib on tumor growth and tumor angiogenesis through molecular factors representative of vascular endothelial growth factor receptors (VEGFR-2) and platelet-derived growth factor receptors (PDGFR-β) families, and of apoptosis (Bcl-2), and of proliferation (Ki67). The Ki67 and Von Willebrand factor expression of the control group was higher than that of the treated group. However, there was no significant difference observed between treated and control groups for apoptosis induction (Bcl-2). Immunohistochemistry, Western blot, and quantitative polymerase chain reaction results showed both VEGFR-2 and PDGFR-β expression in the control group was higher than that of the sunitinib-treated group.

Conclusion

Sunitinib is safe and effective for treating tumors in the course form non-castration to castration groups in LNCaP xenograft prostate tumors. It is potentially beneficial as a prevention and treatment measure for clinical patients with prostate cancer, especially in the course from androgen-dependent prostate cancer to castration-resistant prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Aalinkeel R, Nair MP, Sufrin G, Mahajan SD, Chadha KC et al (2004) Gene expression of angiogenic factors correlates with metastatic potential of prostate cancer cells. Cancer Res 64:5311–5321

    Article  PubMed  CAS  Google Scholar 

  • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2:471–478

    PubMed  CAS  Google Scholar 

  • Barry M, Perner S, Demichelis F, Rubin MA (2007) TMPRSS2–ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology 70:630–633

    Article  PubMed  Google Scholar 

  • Crawford ED (2009) Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 73:S4–S10

    Article  PubMed  Google Scholar 

  • Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C et al (2008) Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 270:229–233

    Article  PubMed  CAS  Google Scholar 

  • Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  PubMed  CAS  Google Scholar 

  • Dong L, Jane B, Yuwei W, Marianne DS, Maisa Y et al (2010) Development of metastatic and non-metastatic tumor lines from a patient’s prostate cancer specimen (identification of a small subpopulation with metastatic potential in the primary tumor. Prostate 70:1636–1644

    Article  Google Scholar 

  • Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG et al (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605

    Article  Google Scholar 

  • Fischel JL, Ciccolini J, Formento P, Ferrero JM, Milano G (2006) Synergistic cytotoxic interaction in hormone refractory prostate cancer with the triple combination docetaxel-erlotinib and 5′DFUR. Experimental data. Anticancer Drugs 17:807–813

    Article  PubMed  CAS  Google Scholar 

  • Guérin O, Formento P, Lo Nigro C, Hofman P, Fischel JL et al (2008) Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 134:51–57

    Article  PubMed  Google Scholar 

  • Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ (2003) Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9:1200–1210

    PubMed  CAS  Google Scholar 

  • Kim SJ, Uehara H, Yazici S, Langley RR, He J et al (2004) Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice. Cancer Res 64:4201–4208

    Article  PubMed  CAS  Google Scholar 

  • Kim SJ, Uehara H, Yazici S, Busby JE, Nakamura T et al (2006) Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer. J Natl Cancer Inst 98:783–793

    Article  PubMed  CAS  Google Scholar 

  • Kim SJ, Kim CH, Ahn JH, Kim MS, Kim SC, Lee SY et al (2007) Time sequence of airway remodelling in a mouse model of chronic asthma: the relation with airway hyper-responsiveness. J Korean Med Sci 22:183–191

    Article  PubMed  CAS  Google Scholar 

  • Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet derived growth factor receptors: determination of a pharmacokinetic pharmacodynamic relationship. Clin Cancer Res 9:327–337

    PubMed  CAS  Google Scholar 

  • Merk J, Rolff J, Becker M, Leschber G, Fichtner I (2009) Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy? Eur J Cardiothorac Surg 36:454–459

    Article  PubMed  Google Scholar 

  • Michaelson M, Dror Regan MM, Oh WK, Kaufman DS, Olivier K et al (2009) Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20:913–920

    Article  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  PubMed  CAS  Google Scholar 

  • O’Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL et al (2003) An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9:5465–5476

    PubMed  Google Scholar 

  • Perryman LA, Blair JM, Kingsley EA, Szymanska B, Ow KT et al (2006) Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. Biochem Biophys Res Commun 345:1207–1214

    Article  PubMed  CAS  Google Scholar 

  • Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen independent prostate cancer. Clin Cancer Res 12:1665–1671

    Article  PubMed  CAS  Google Scholar 

  • Polyzos A (2008) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J Steroid Biochem Mol Biol 108:261–266

    Article  PubMed  CAS  Google Scholar 

  • Sharpless NE, Depinho RA (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5:741–754

    Article  PubMed  CAS  Google Scholar 

  • Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E et al (2012) Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol 2:707–714

    Article  Google Scholar 

  • Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT et al (2010) Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 21:319–324

    Article  PubMed  CAS  Google Scholar 

  • Strohmeyer D, Strauss F, Rossing C, Roberts C, Kaufmann O et al (2004) Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res 24:1797–1804

    PubMed  CAS  Google Scholar 

  • Su B, Zheng Q, Vaughan MM, Bu Y, Gelman IH (2006) SSeCKS metastasis-suppressing activity in MatLyLu prostate cancer cells correlates with vascular endothelial growth factor inhibition. Cancer Res 66:5599–5607

    Article  PubMed  CAS  Google Scholar 

  • SUTENT (sunitinib malate) (2006) Prescribing information. Pfzer Inc, New York

  • Tang Y, Hamburger AW, Wang L, Khan MA, Hussain A (2009) Androgen deprivation and stem cell markers in prostate cancers. Int J Clin Exp Pathol 3:128–138

    PubMed  Google Scholar 

  • Verras M, Lee J, Xue H, Li T, Wang Y et al (2007) The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 67:967–975

    Article  PubMed  CAS  Google Scholar 

  • Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR et al (2005) An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 85:1392–1404

    Article  PubMed  Google Scholar 

  • Zheng X, Cui XX, Gao Z, Zhao Y, Lin Y et al (2010) Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence. Cancer Prev Res (Phila) 3:114–124

    Article  CAS  Google Scholar 

  • Zheng X, Cui XX, Gao Z, Zhao Y, Shi Y et al (2011) Inhibitory effect of dietary atorvastatin and celecoxib together with voluntary running wheel exercise on the progression of androgen-dependent LNCaP prostate tumors to androgen independence. Exp Ther Med 2:221–228

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by Science Foundation of Tianjin medical university (NO: 2009GSI18).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Urology, Secondary Hospital of Tianjin Medical University, Tianjin Institute of Urology, Ping Jiang Road 23, He Xi District, Tianjin, 300211, China

    Chen Jing, Jiang Ning & Niu Yuanjie

Authors
  1. Chen Jing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiang Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Niu Yuanjie
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Niu Yuanjie.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jing, C., Ning, J. & Yuanjie, N. The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors. J Cancer Res Clin Oncol 138, 2137–2143 (2012). https://doi.org/10.1007/s00432-012-1295-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-012-1295-y

Keywords

Search

Navigation